News

Bristol Myers Squibb (BMY) ended the recent trading session at $48.02, demonstrating a +2.85% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.
Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...
To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...
Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...
Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...
This was the stock's second consecutive day of losses.
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...
Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...